Literature DB >> 23147577

Diabetes: long-acting insulin analogues--are benefits worth the cost?

David M Nathan.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23147577     DOI： 10.1038/nrendo.2012.208

Source DB:  PubMed          Journal:  Nat Rev Endocrinol        ISSN： 1759-5029            Impact factor:   43.330


× No keyword cloud information.
  10 in total

1.  Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes.

Authors:  Ian H de Boer; Wanjie Sun; Patricia A Cleary; John M Lachin; Mark E Molitch; Michael W Steffes; Bernard Zinman
Journal:  N Engl J Med       Date:  2011-11-12       Impact factor: 91.245

2.  Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes.

Authors:  David M Nathan; Patricia A Cleary; Jye-Yu C Backlund; Saul M Genuth; John M Lachin; Trevor J Orchard; Philip Raskin; Bernard Zinman
Journal:  N Engl J Med       Date:  2005-12-22       Impact factor: 91.245

3.  Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial.

Authors:  Simon Heller; John Buse; Miles Fisher; Satish Garg; Michel Marre; Ludwig Merker; Eric Renard; David Russell-Jones; Areti Philotheou; Ann Marie Ocampo Francisco; Huiling Pei; Bruce Bode
Journal:  Lancet       Date:  2012-04-21       Impact factor: 79.321

Review 4.  Revisiting the efficacy of long-acting insulin analogues on adults with type 1 diabetes using mixed-treatment comparisons.

Authors:  Andréia Cristina Conegero Sanches; Cassyano Januário Correr; Rafael Venson; Roberto Pontarolo
Journal:  Diabetes Res Clin Pract       Date:  2011-10-11       Impact factor: 5.602

5.  Insulin availability among International Diabetes Federation member associations. Report of the Task Force on Insulin Distribution.

Authors:  L C Deeb; M H Tan; K G Alberti
Journal:  Diabetes Care       Date:  1994-03       Impact factor: 19.112

6.  The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.

Authors:  D M Nathan; S Genuth; J Lachin; P Cleary; O Crofford; M Davis; L Rand; C Siebert
Journal:  N Engl J Med       Date:  1993-09-30       Impact factor: 91.245

Review 7.  Long-acting insulin analogues vs. NPH human insulin in type 1 diabetes. A meta-analysis.

Authors:  M Monami; N Marchionni; E Mannucci
Journal:  Diabetes Obes Metab       Date:  2009-04       Impact factor: 6.577

8.  Insulin degludec/insulin aspart administered once daily at any meal, with insulin aspart at other meals versus a standard basal-bolus regimen in patients with type 1 diabetes: a 26-week, phase 3, randomized, open-label, treat-to-target trial.

Authors:  Irl B Hirsch; Bruce Bode; Jean-Pierre Courreges; Patrik Dykiel; Edward Franek; Kjeld Hermansen; Allen King; Henriette Mersebach; Melanie Davies
Journal:  Diabetes Care       Date:  2012-08-28       Impact factor: 19.112

9.  Insulin degludec in type 1 diabetes: a randomized controlled trial of a new-generation ultra-long-acting insulin compared with insulin glargine.

Authors:  Kåre I Birkeland; Philip D Home; Ulrich Wendisch; Robert E Ratner; Thue Johansen; Lars A Endahl; Karsten Lyby; Johan H Jendle; Anthony P Roberts; J Hans DeVries; Luigi F Meneghini
Journal:  Diabetes Care       Date:  2011-01-26       Impact factor: 19.112

10.  Comparison of once- versus twice-daily administration of insulin detemir, used with mealtime insulin aspart, in basal-bolus therapy for type 1 diabetes: assessment of detemir administration in a progressive treat-to-target trial (ADAPT).

Authors:  Jean-Pierre Le Floch; Marc Lévy; Helen Mosnier-Pudar; Frank Nobels; Sylvie Laroche; Sophie Gonbert; Eveline Eschwege; Pierre Fontaine
Journal:  Diabetes Care       Date:  2008-10-22       Impact factor: 19.112
  10 in total
  1 in total

1.  A programmable synthetic lineage-control network that differentiates human IPSCs into glucose-sensitive insulin-secreting beta-like cells.

Authors:  Pratik Saxena; Boon Chin Heng; Peng Bai; Marc Folcher; Henryk Zulewski; Martin Fussenegger
Journal:  Nat Commun       Date:  2016-04-11       Impact factor: 14.919
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.